EA202191588A1 - Замещенные ксантиновые производные - Google Patents

Замещенные ксантиновые производные

Info

Publication number
EA202191588A1
EA202191588A1 EA202191588A EA202191588A EA202191588A1 EA 202191588 A1 EA202191588 A1 EA 202191588A1 EA 202191588 A EA202191588 A EA 202191588A EA 202191588 A EA202191588 A EA 202191588A EA 202191588 A1 EA202191588 A1 EA 202191588A1
Authority
EA
Eurasian Patent Office
Prior art keywords
xanthine derivatives
substituted xanthine
substituted
trpc5
therapy
Prior art date
Application number
EA202191588A
Other languages
English (en)
Russian (ru)
Inventor
Кай Герлах
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Хайдра Байосайенсиз, Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх, Хайдра Байосайенсиз, Ллк filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA202191588A1 publication Critical patent/EA202191588A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA202191588A 2018-12-12 2019-12-10 Замещенные ксантиновые производные EA202191588A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18212060 2018-12-12
PCT/EP2019/084375 WO2020120450A1 (en) 2018-12-12 2019-12-10 Substituted xanthine derivatives

Publications (1)

Publication Number Publication Date
EA202191588A1 true EA202191588A1 (ru) 2021-10-18

Family

ID=64665184

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191588A EA202191588A1 (ru) 2018-12-12 2019-12-10 Замещенные ксантиновые производные

Country Status (18)

Country Link
US (2) US11198696B2 (cg-RX-API-DMAC7.html)
EP (1) EP3894410B1 (cg-RX-API-DMAC7.html)
JP (1) JP7502299B2 (cg-RX-API-DMAC7.html)
KR (1) KR102877857B1 (cg-RX-API-DMAC7.html)
CN (1) CN113166151B (cg-RX-API-DMAC7.html)
AU (1) AU2019396499B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008316A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021001509A1 (cg-RX-API-DMAC7.html)
DK (1) DK3894410T3 (cg-RX-API-DMAC7.html)
EA (1) EA202191588A1 (cg-RX-API-DMAC7.html)
ES (1) ES2964630T3 (cg-RX-API-DMAC7.html)
HU (1) HUE064908T2 (cg-RX-API-DMAC7.html)
IL (1) IL283768B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007019A (cg-RX-API-DMAC7.html)
PH (1) PH12021551345A1 (cg-RX-API-DMAC7.html)
PL (1) PL3894410T3 (cg-RX-API-DMAC7.html)
TW (1) TWI825243B (cg-RX-API-DMAC7.html)
WO (1) WO2020120450A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12064917B2 (en) 2012-11-21 2024-08-20 Stratasys, Inc. Method for printing three-dimensional parts with cyrstallization kinetics control
IL283768B2 (en) * 2018-12-12 2024-05-01 Boehringer Ingelheim Int Xanthine histories are transmuted
KR20250141831A (ko) * 2023-02-08 2025-09-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 잔틴계 화합물 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370372B (es) 2013-03-15 2019-12-11 Hydra Biosciences Inc Xantinas sustituidas y metodos de uso de las mismas.
EP3180340B1 (en) 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
JP7114702B2 (ja) * 2017-07-11 2022-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規置換キサンチン誘導体
IL283768B2 (en) * 2018-12-12 2024-05-01 Boehringer Ingelheim Int Xanthine histories are transmuted

Also Published As

Publication number Publication date
PL3894410T3 (pl) 2024-03-18
HUE064908T2 (hu) 2024-04-28
ES2964630T3 (es) 2024-04-08
BR112021008316A2 (pt) 2021-08-03
KR20210102955A (ko) 2021-08-20
US11198696B2 (en) 2021-12-14
CN113166151A (zh) 2021-07-23
DK3894410T3 (da) 2023-11-27
IL283768A (en) 2021-07-29
CN113166151B (zh) 2023-12-01
TWI825243B (zh) 2023-12-11
JP7502299B2 (ja) 2024-06-18
CA3119229A1 (en) 2020-06-18
KR102877857B1 (ko) 2025-10-29
EP3894410B1 (en) 2023-10-11
EP3894410A1 (en) 2021-10-20
TW202039495A (zh) 2020-11-01
US20200190093A1 (en) 2020-06-18
MX2021007019A (es) 2021-09-10
IL283768B1 (en) 2024-01-01
US20220177479A1 (en) 2022-06-09
WO2020120450A1 (en) 2020-06-18
CL2021001509A1 (es) 2021-12-17
PH12021551345A1 (en) 2022-05-11
AU2019396499A1 (en) 2021-05-27
AU2019396499B2 (en) 2024-10-10
IL283768B2 (en) 2024-05-01
JP2022512373A (ja) 2022-02-03

Similar Documents

Publication Publication Date Title
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
PH12021551065A1 (en) Fused ring compounds
PH12021500014A1 (en) Fused ring compounds
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201791727A1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
JO3807B1 (ar) مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
EA201890165A1 (ru) Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа
EA201692280A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX2016009403A (es) Compuestos heterociclicos.
PH12021500034A1 (en) Compounds useful in hiv therapy
MD20160053A2 (ro) Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201990400A1 (ru) Соединения и композиции и их применение
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202090270A1 (ru) Новые замещенные производные ксантина
EA201892382A1 (ru) Замещенные бициклические гетероциклические соединения